Unicycive Therapeutics Stock Forum

$Unicycive Therapeutics (UNCY.US)$ Is this starting to come alive?

$Unicycive Therapeutics (UNCY.US)$
H.C. Wainwright raised the firm’s  on Unicycive Therapeutics () to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
Published first on  – the ultimate source for real-time, market-moving breaking financ

$Unicycive Therapeutics (UNCY.US)$
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Positive
FDA acceptance of OLC New Drug Application with PDUFA date set for June 28, 2025
Strong patient preference for OLC: 79% preferred it over prior therapy
Successful completion of UNI-494 Phase 1 trial with positive safety profile
Patent granted for UNI-494 valid until 2040
Cash runway extended into 2026 with $32.3M cash position
Reduced net loss to $4.1M from $4.4...

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics announced FDA acceptance of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The FDA set a PDUFA target date of June 28, 2025. OLC aim...

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics (UNCY) presented multiple studies at ASN Kidney Week 2024, highlighting progress on oxylanthanum carbonate (OLC) and UNI-494. The late-breaking presentation showed OLC enabled serum phosphate control in >90% of chronic kidney disease pati...

$Unicycive Therapeutics (UNCY.US)$  has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

$Unicycive Therapeutics (UNCY.US)$ poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA.

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics (Nasdaq: UNCY) announced a late-breaker poster presentation on oxylanthanum carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024. The presentation, titled 'Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphospha...